Paul G. Richardson

TL;DR: The Pivotal Part 2 of STORM was initiated, enrolling an additional cohort of 122 patients with penta-refractory MM, and demonstrated an overall response rate (ORR) of 21% that met the inclusion criteria for STORM.

TL;DR: A cancer vaccine in which dendritic cells are fused to autologous tumor cells resulting in the presentation of multiple tumor antigens with the capacity to elicit a broad anti-tumor response was developed, which resulted in the eradication of post-transplant measurable disease.

TL;DR: RVD lite is a well-tolerated and highly effective regimen in the transplant-ineligible population with robust PFS and OS and the data demonstrates that the benefits of more effective combination strategies observed in younger, fitter, transplant-eligible patients to older, transplanted patients with modifications in dose and schedule, without compromising efficacy.

TL;DR: This analysis evaluated whether the efficacy and tolerability of POM+LoDEX treatment is consistent across age subgroups and found the most common treatment emergent grade 3/4 adverse events (AEs) for the age sub groups accorded.

TL;DR: This study shows that self-reported data on HIV testing history and ART may not be accurate and that ARV drug testing can help identify persons who are aware of their HIV-positive status and are on ART.